Inmagene Biopharmaceutical ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") announce that the first participant, based in the United States, was dosed in a global Phase...
Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed...
